Related Experiment Videos
Screening for Type 2 diabetes mellitus: a decision analytic approach
1Department of Public Health & Community Medicine, University of Sydney, Australia. e.goyder@sheffield.ac.uk
Diabetic Medicine : a Journal of the British Diabetic Association
|September 7, 2000
Summary
Screening for asymptomatic Type 2 diabetes may offer minimal benefits, with potential harms from early diagnosis outweighing long-term gains. Cardiovascular risk is key in deciding on diabetes screening effectiveness.
Area of Science:
- Endocrinology
- Preventive Medicine
- Health Economics
Background:
- Type 2 diabetes mellitus is prevalent, causing significant morbidity and mortality.
- The benefits of early treatment for asymptomatic diabetes remain uncertain.
- Screening effectiveness depends on balancing potential benefits against harms.
Purpose of the Study:
- To determine if screening for asymptomatic Type 2 diabetes mellitus outweighs potential harm.
- To identify variables influencing the benefit-harm balance of screening.
Main Methods:
- Decision analysis comparing screening (ages 45-60) with no screening.
- Model evaluated quality-adjusted life years (QALYs) gained from reduced complications versus lost from early diagnosis.
Main Results:
- Screening yielded a net gain of 10 QALYs per 10,000 individuals.
- Gains from microvascular and cardiovascular complications were offset by losses from early diagnosis.
- Benefit-harm balance is sensitive to cardiovascular risk and intervention effectiveness.
Conclusions:
- Immediate harms of early diagnosis and treatment may exceed long-term benefits.
- Screening decisions should prioritize cardiovascular risk assessment.
- Availability of evidence-based interventions is crucial for effective screening.